DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide ( IDegLira ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
| العنوان: | |
|---|---|
| المؤلفون: | Jun Liu, Yibing Lu, Tomoyuki Nishida, Yu Pei, Lei Liu, Dongmei Li, Bue R. Agner, Bin Luo, Ming Liu, Xiangjin Xu, Yiming Mu, Xiaolin Dong |
| المصدر: | Diabetes, Obesity and Metabolism. 23:2687-2696 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Insulin degludec, medicine.medical_specialty, Liraglutide, business.industry, Endocrinology, Diabetes and Metabolism, Insulin, medicine.medical_treatment, Type 2 diabetes, medicine.disease, Gastroenterology, law.invention, Metformin, Endocrinology, Randomized controlled trial, law, Weight loss, Internal medicine, Internal Medicine, medicine, Clinical endpoint, medicine.symptom, business, medicine.drug |
| الوصف: | AIM To assess the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (degludec) in Chinese people with type 2 diabetes (T2D) treated with basal insulin. MATERIALS AND METHODS In DUAL II China, a randomized, double-blinded, multicentre, treat-to-target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26 weeks of treatment with either IDegLira (max. dose 50 U degludec/1.8 mg liraglutide) or degludec (max. 50 U/day), respectively, combined with metformin. At 26 weeks, superiority of IDegLira over degludec was assessed for change in HbA1c (primary endpoint), and body weight and number of severe or blood glucose (BG)-confirmed hypoglycaemic episodes (confirmatory secondary endpoints). RESULTS Overall, 453 participants were randomized to IDegLira (n = 302) or degludec (n = 151). Superiority was confirmed for IDegLira over degludec in HbA1c change (-1.9% vs. -1.0%, respectively, estimated treatment difference [ETD] [95% confidence interval]: -0.92% [-1.09; -0.75], P |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::1ce033c4daa8745ee28648906a70e240Test https://doi.org/10.1111/dom.14522Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........1ce033c4daa8745ee28648906a70e240 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|